Methanethiosulfonate derivatives of rhodamine and verapamil activate human P-glycoprotein at different sites.
The human multidrug resistance P-glycoprotein (P-gp, ABCB1) actively extrudes a broad range of potentially cytotoxic compounds out of the cell. Key steps in understanding the transport process are binding of drug substrates in the transmembrane domains, initiation of ATPase activity, and subsequent drug efflux. We used cysteine-scanning mutagenesis of the transmembrane segment residues and reaction with the thiol-reactive drug substrate analog of rhodamine, methane-thiosulfonate-rhodamine (MTS-rhodamine), to test whether P-gp could be trapped in an activated state with high levels of ATPase activity. The presence of such an activated P-gp could be used to further investigate P-gp-drug substrate interactions. Single cysteine mutants (149) were treated with MTS-rhodamine, and ATPase activities were determined after removal of unreacted MTS-rhodamine. One mutant, F343C(TM6), showed a 5.8-fold increase in activity after reaction with MTS-rhodamine. Pre-treatment of mutant F343C with rhodamine B protected it from activation by MTS-rhodamine, indicating that residue Cys-343 contributes to the rhodamine-binding site. The ATPase activity of MTS-rhodamine-treated mutant F343C, however, was not stimulated further by colchicine or calcein-AM. By contrast, verapamil and Hoechst 33342 stimulated and inhibited, respectively, the ATPase activity of the MTS-rhodamine-treated mutant F343C. These results indicate that the MTS-rhodamine binding site overlaps that of colchicine and calcein-AM but not that of verapamil and Hoechst 33342 within the common drug-binding pocket.
Loo
Tip W
TW
Canadian Institutes of Health Research Group in Membrane Biology, Departments of Medicine and Biochemistry, University of Toronto, Toronto, Ontario M5S 1A8, Canada.
Bartlett
M Claire
MC
Clarke
David M
DM
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000737:chemistry*; D000251:Adenosine Triphosphatases / Q000737:chemistry; D001562:Benzimidazoles / Q000494:pharmacology; D001665:Binding Sites; D001692:Biological Transport; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002460:Cell Line; D003078:Colchicine / Q000737:chemistry; D003545:Cysteine / Q000737:chemistry / Q000235:genetics; D018076:DNA, Complementary / Q000378:metabolism; D004220:Disulfides; D004305:Dose-Response Relationship, Drug; D005452:Fluoresceins / Q000737:chemistry; D005456:Fluorescent Dyes / Q000737:chemistry / Q000494:pharmacology; D006639:Histidine / Q000737:chemistry; D006801:Humans; D008698:Mesylates / Q000737:chemistry*; D008954:Models, Biological; D008956:Models, Chemical; D009154:Mutation; D011485:Protein Binding; D017433:Protein Structure, Secondary; D017434:Protein Structure, Tertiary; D012235:Rhodamines / Q000737:chemistry*; D014700:Verapamil / Q000031:analogs & derivatives*
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D001562:Benzimidazoles; D002121:Calcium Channel Blockers; D018076:DNA, Complementary; D004220:Disulfides; D005452:Fluoresceins; D005456:Fluorescent Dyes; D008698:Mesylates; D012235:Rhodamines; C085925:calcein AM; C074502:methanethiosulfonate; D006639:Histidine; D014700:Verapamil; D000251:Adenosine Triphosphatases; C029773:rhodamine B; D003545:Cysteine; C017807:bisbenzimide ethoxide trihydrochloride; D003078:Colchicine